Form 4 for NGNE Neurogene Inc.
Accepted 2024-03-14 00:00:00 ET · period of report 2024-03-13 · accession 0001404644-24-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-14 | 2024-03-13 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +31.9K | 52.8K | +152% | $0 |
| D | 2024-03-14 | 2024-03-13 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +53.9K | 53.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-13 | A | A | 31,903 | $0.00 | 52,844 | D | — | — | |
| 2 | Derivative | Employee Stock Option (Right to buy) | 2024-03-13 | A | A | 53,900 | $0.00 | 53,900 | D | $36.06 · — to 2034-03-13 | 53,900 Common Stock | (F1) The option vests as to 1/4 of the total number of shares on March 13, 2025, and then 1/48 of the total number of shares will vest monthly thereafter, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. |